AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), Arcus Biosciences ((RCUS)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AstraZeneca, in collaboration with Arcus Biosciences, is conducting a global Phase III study titled ‘A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy.’ The study aims to evaluate the efficacy and safety of combining durvalumab with domvanalimab in treating patients with Stage III unresectable non-small cell lung cancer (NSCLC).
The study is testing two interventions: Durvalumab, an immunotherapy drug, and Domvanalimab, an investigational antibody. These are administered via intravenous infusion every four weeks for up to 12 months, aiming to enhance the immune response against cancer cells.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment, focusing on improving patient outcomes in NSCLC.
The study began on February 18, 2022, and is currently recruiting participants. The primary completion date is projected for June 23, 2025, with the same date estimated for the overall study completion. These timelines are crucial for investors tracking the progress and potential market entry of these treatments.
The outcome of this study could significantly impact AstraZeneca and Arcus Biosciences’ stock performance, as successful results may lead to new treatment approvals and increased market share in the oncology sector. Investors should also consider the competitive landscape, as advancements in NSCLC treatments are highly sought after in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.